| 保荐人名称：招商证券股份有限公司 | 被保荐公司简称：东宝生物 | | --- | --- | | 保荐代表人姓名：留梦佳 | 联系电话：021-58835130 | | 保荐代表人姓名：周冰昱 | 联系电话：021-58835130 | 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 不适用 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 | 是 | | 限于防止关联方占用公司资源的制度、募集资金 | | | 管理制度、内控制度、内部审计制度、关联交易 | | | 制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月 1 次 | | （2）公司募集资金项目进展是否与信息披露文件 | 是 | | 一致 | | | 4.公司治理督导情况 | | | （1）列席公司股东大会次数 | 2 次， ...

每经头条（nbdtoutiao）——人口流失、土地闲置的城市要不要撤并？专访国家发改委专家高国力：未 来不排除，目前没到这阶段 （记者 曾健辉） 2024年1至12月份，东宝生物的营业收入构成为：生物和生化制品占比100.0%。 截至发稿，东宝生物市值为34亿元。 每经AI快讯，东宝生物（SZ 300239，收盘价：5.69元）9月2日晚间发布公告称，截至2025年8月31日， 公司累计通过股份回购专用证券账户以集中竞价交易方式回购公司股份约1057万股，占公司当前总股本 的1.7812%，最高成交价为5.71元/股，最低成交价为4.59元/股，成交总金额为人民币约5611万元。 ...

格隆汇9月2日丨东宝生物（维权）(300239.SZ)公布，截至2025年8月31日，公司累计通过股份回购专用 证券账户以集中竞价交易方式回购公司股份10,573,400股，占公司当前总股本的1.7812%，最高成交价 为5.71元/股，最低成交价为4.59元/股，成交总金额为人民币5611.01万元(不含交易费用)。 ...

包头东宝生物技术股份有限公司(以下简称"东宝生物"或"公司")于2025 年1月3日召开第九届董事会第八次会议、第九届监事会第七次会议，审议通过了 《关于回购公司股份方案的议案》，使用公司自有资金和/或自筹资金以集中竞 价交易方式或法律法规允许的方式回购公司已发行的人民币普通股(A股)股票， 回购的公司股份用于实施员工持股计划或股权激励。本次回购股份不低于人民币 5,000万元(含)，且不超过人民币10,000万元(含)，具体回购资金总额以回购期限 届满时或者回购股份实施完毕时实际回购股份使用的成交资金总额为准。本次回 购价格不超过人民币8.00元/股(含)，本次回购股份的实施期限自公司董事会审议 通过回购股份方案之日起12个月内。因公司实施2024年度权益分派，公司本次回 购价格上限由不超过人民币8.00元/股(含)调整为不超过人民币7.98元/股(含)。具 体内容详见公司在巨潮资讯网(www.cninfo.com.cn)上披露的《回购股份报告书》 (公告编号：2025-009)、《关于2024年度权益分派实施后调整回购股份价格上限 和数量的公告》（公告编号：2025-049）等相关公告。 一、回购股份进展 ...

Financial Performance - Dongbao Biological reported a net profit decline of 28% year-on-year for the first half of 2025, with total revenue of 369 million yuan, down 16.93% compared to the previous year [1] - The gross profit margin increased to 25.44%, a year-on-year increase of 12.25%, while the net profit margin decreased to 10.02%, down 19.73% [1] - Total expenses (selling, administrative, and financial) reached 34.68 million yuan, accounting for 9.4% of revenue, which is a 56.8% increase year-on-year [1] Key Financial Metrics - Revenue for the second quarter of 2025 was 181 million yuan, a decrease of 10.61% year-on-year, with a net profit of 17.92 million yuan, down 29.38% [1] - The company’s cash and cash equivalents decreased by 34.72% to 521 million yuan, while accounts receivable increased by 16.46% to 191 million yuan [1] - The return on invested capital (ROIC) for the previous year was 3.79%, indicating weak capital returns, with a historical median ROIC of 3.16% over the past decade [3] Debt and Cash Flow - The company has a healthy cash position, but the interest-bearing debt ratio has reached 20.13% [4] - The accounts receivable to profit ratio is at 221.88%, indicating potential concerns regarding cash flow management [4] Operational Strategies - The company has implemented measures to enhance cost control, including optimizing supply chain management and improving supplier relationships [5] - Emphasis on quality control through a management philosophy focused on prevention, control, and improvement, aiming to ensure product quality and cost efficiency [5]

Core Insights - Dongbao Biological achieved operating revenue of 369 million yuan and a net profit attributable to shareholders of 36.97 million yuan in the first half of 2025 [1] - The company focuses on the natural collagen sector and implements a health development strategy amid uncertainties in the external environment, particularly in the gelatin market [1][2] - Dongbao Biological is actively responding to market challenges through product segmentation, exploring new application fields, and enhancing digital transformation [1][2] Financial Performance - In the first half of 2025, Dongbao Biological's revenue was 369 million yuan, with a net profit of 36.97 million yuan [1] - The company faced short-term declines in sales and prices due to fluctuations in the gelatin market [1] Strategic Initiatives - Dongbao Biological is enhancing its research and development system, focusing on demand-driven innovation and application breakthroughs [2] - The company is advancing various projects, including specialized collagen for cashmere textiles and low-endotoxin gelatin, which are in the process of market engagement [2] - The company is also pushing for the industrialization of hair care collagen products and expanding its product matrix into multiple application fields [2][3] Market Positioning - Dongbao Biological is committed to developing high-value-added collagen derivatives, maintaining its leading position in the natural collagen industry [3] - The company aims to evolve into a comprehensive enterprise group in the health industry, focusing on medical, beauty, health, and food sectors [3]

Core Viewpoint - Dongbao Biological reported a revenue of 369 million yuan and a net profit of 36.97 million yuan for the first half of 2025, demonstrating resilience in a complex market environment through strategic market exploration and cost reduction initiatives [1] Group 1: Market Strategy and Performance - The company focused on the collagen industry strategy, enhancing operational efficiency through refined management and organizational improvements [2] - Dongbao Biological initiated a stock repurchase plan, buying back 10.57 million shares, representing 1.78% of its total share capital, to enhance shareholder value and investor confidence [2] - The company achieved significant growth in its gelatin segment, particularly in the blood plasma gelatin market, and saw an increase in revenue from its hollow capsule products [2] Group 2: Product Development and Innovation - Key R&D projects made substantial progress, including improvements in anti-pilling levels for collagen used in cashmere textiles and advancements in low-endotoxin gelatin [3] - The company is advancing its collagen products for hair care and has initiated market connections for various modified gelatin applications [3] Group 3: Industry Outlook and Growth Potential - Despite short-term performance pressures, the company is well-positioned for long-term growth due to its comprehensive production capabilities, management advantages, and strong R&D platform [4] - The pharmaceutical excipients market, particularly for hollow capsules, is expected to expand due to policy support and technological innovations, benefiting leading companies like Dongbao Biological [4] - The growing health consciousness among consumers is driving demand for nutritional health products and beauty care, creating new opportunities for collagen applications [4] Group 4: Expanding Applications and Market Opportunities - The introduction of blood plasma gelatin is extending the company's applications into the medical field, with potential uses in various medical products and procedures [5] - The "Healthy China" initiative is fostering a supportive policy environment for the health industry, which is expected to enhance market demand for high-quality health products [5][6] - Dongbao Biological is positioned to benefit from the ongoing high-quality development in the health sector, leveraging its management, technology, and brand advantages [6]

Group 1 - Dongbao Biological (SZ 300239) announced on August 29 that its 12th meeting of the 9th board of directors was held on August 28, 2025, in Baotou, where the proposal to revise the "Information Disclosure Management System" was reviewed [1] - For the year 2024, Dongbao Biological's revenue composition is 100.0% from biological and biochemical products [1]

Core Viewpoint - Dongbao Bio (300239.SZ) reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first half of 2025 was 369 million yuan, a year-on-year decrease of 16.93% [1] - The net profit attributable to shareholders of the listed company was 36.97 million yuan, reflecting a year-on-year decrease of 28.00% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 33.44 million yuan, down 27.41% year-on-year [1] - Basic earnings per share were reported at 0.0629 yuan [1]

Core Viewpoint - Dongbao Biological (300239.SZ) reported a decline in revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved operating revenue of 369 million yuan, a year-on-year decrease of 16.93% [1] - The net profit attributable to shareholders was 36.97 million yuan, down 28.00% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 33.44 million yuan, reflecting a 27.41% decline compared to the previous year [1] - Basic earnings per share were reported at 0.0629 yuan [1]